$ENTX Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting Read the Full News Release 👉 https://t.co/qpFxCz62ZV

$ENTX In addition, recent reviews in Osteoporosis International & Best Practice & Research Clinical Rheumatology have also highlighted ENTERA’s programs, including EB613 for osteoporosis and EB612 for hypoparathyroidism (3/3)

$ENTX Independent recognition like this underscores the importance of our mission and creates new opportunities to engage with the clinical and scientific community. We look forward to continued dialogue with KOLs, clinicians, and researchers dedicated to bone health. (2/3)

$ENTX Our oral PTH candidate, EB613, was recognized among emerging anabolic therapies, reflecting growing attention to the potential of oral peptides in advancing osteoporosis care. (1/3)

In this brand-new episode of @ThePharmaverse Podcast, Entera Bio CEO Miranda Toledano talks about Entera's vision, pipeline, and her personal story. $ENTX https://t.co/Om6MoWGelB

🚨 On Monday, don't miss Michael Pietrack's interview with Miranda Toledano, CEO of Entera Bio on @ThePharmaverse Podcast $ENTX 🔊

$ENTX Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress Read the Full News Release 👉 https://t.co/v83sLzEUYv

$ENTX Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025 Read the Full News Release 👉 https://t.co/hOtFVLxyzb

$ENTX Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences Read the Full News Release 👉 https://t.co/HELLziXg1W

$ENTX Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates Read the Full News Release 👉 https://t.co/zpOXYs4HJM

$ENTX EB613, an oral anabolic tablet for osteoporosis, gets FDA agreement for phase 3 study with hip BMD as primary endpoint. Aiming to address unmet needs for 200M+ women, it could be the 1st daily oral treatment to boost bone mass & reduce fractures. https://t.co/b2VcF5huxk

$ENTX $OPK oral GLP-2 analog for short bowel syndrome (SBS) to be presented at ESPEN 2025, Prague (Sep 13–16). Combines OPKO’s long-acting agonist with Entera’s N-Tab™ tech, offering a daily tablet alternative to daily injections. https://t.co/OTinMdxzYg

New in-vivo PK and PD data on a dual GLP-1/glucagon agonist oral tablet for obesity & metabolic disorders, to be presented at ENDO 2025 (July 12–15, SF). Developed by $ENTX $OPK https://t.co/yk7wsXELAY

Reduce osteoporosis risk early! In your 20s, build bone mass with calcium (1,000–1,200 mg/day), vitamin D (600–800 IU), and weight-bearing exercise 3–4x/week. Avoid smoking, limit alcohol, stay healthy. Women under 65 with risks: get bone density scans. https://t.co/IG62KjP520

$ENTX EB613, a daily oral PTH(1-34) tablet, boosts BMD in postmenopausal women with osteoporosis. Randomized Phase 2 data on 161 women shows dual action on bone formation & resorption. 3D-DXA analysis to be presented at ASBMR 2025. https://t.co/0XvlEWy86T

$ENTX $OPK to present oral OPK-88006 data at ENDO 2025. Dual GLP-1/glucagon agonist tablet targets obesity & metabolic disorders. FDA IND filing planned for 2025, with Phase 1 being planned. Details:

Menopause isn’t a time to shrink back, it’s a time to stand in your power, with strength from the inside out. What every woman needs to know about bone loss during menopause! Article by Dr. Marva Williams (Hons) on @ElysiumWomenMag https://t.co/QdGA2xzYoG #osteoporosis

50+ trials with 170,000 patients show hip BMD increase over 24 months predicts fracture risk reduction. STEs: 1.43% for vertebral, 2.04% for clinical, 2.13% for non-vertebral, 3.07% for hip fractures. The FDA is reviewing BMD as surrogate endpoint for new osteoporosis drugs.

AMWA's osteoporosis hub educates clinicians & public on this "silent" disease. Learn prevention via nutrition, exercise, lifestyle & screening. Discover risk factors & why early detection matters https://t.co/3QBIUa6J1y

GLP-1 weight loss drugs like Ozempic & Wegovy may increase osteoporosis risk, as 40% of weight loss is muscle & bone mass, per Univ. of Liverpool study. ROS warns of brittle bone risk. Full story: